Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis

Tiziano Barbui, Jürgen Thiele, Alessandra Carobbio, Francesco Passamonti, Elisa Rumi, Maria Luigia Randi, Irene Bertozzi, Alessandro M. Vannucchi, Heinz Gisslinger, Bettina Gisslinger, Guido Finazzi, Marco Ruggeri, Francesco Rodeghiero, Alessandro Rambaldi, Naseema Gangat, Ayalew Tefferi

Research output: Contribution to journalArticle

Abstract

In the present study, we investigated disease characteristics and clinical outcome in young patients (<40 years) with World Health Organization (WHO)-defined essential thrombocythemia (ET) compared with early/prefibrotic primary myelofibrosis (PMF) with presenting thrombocythemia. We recruited 213 young patients (median age, 33.6 years), ncluding 178 patients (84%) with WHO-defined ET and 35 patients (16%) showing early PMF. Median follow-up time was 7.5 years. A trend for more overall thrombotic complications, particularly arterial, was seen in early PMF compared with ET. Progression to overt myelofibrosis was 3% in ET and 9% in early PMF, but no transformation into acute leukemia was observed. Combining all adverse events (thrombosis, bleeding, and myelofibrosis), the rate was significantly different (1.29% vs 3.43% of patients/year, P = .01) in WHO-ET and early PMF, respectively. In multivariate analysis, early PMF and the JAK2V617F mutation emerged as independent factors predicting cumulative adverse events.

Original languageEnglish
Pages (from-to)569-571
Number of pages3
JournalBlood
Volume120
Issue number3
DOIs
Publication statusPublished - Jul 19 2012

Fingerprint

Essential Thrombocythemia
Primary Myelofibrosis
Young Adult
Health
Thrombocytosis
Leukemia
Thrombosis
Multivariate Analysis
Hemorrhage
Mutation

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. / Barbui, Tiziano; Thiele, Jürgen; Carobbio, Alessandra; Passamonti, Francesco; Rumi, Elisa; Randi, Maria Luigia; Bertozzi, Irene; Vannucchi, Alessandro M.; Gisslinger, Heinz; Gisslinger, Bettina; Finazzi, Guido; Ruggeri, Marco; Rodeghiero, Francesco; Rambaldi, Alessandro; Gangat, Naseema; Tefferi, Ayalew.

In: Blood, Vol. 120, No. 3, 19.07.2012, p. 569-571.

Research output: Contribution to journalArticle

Barbui, T, Thiele, J, Carobbio, A, Passamonti, F, Rumi, E, Randi, ML, Bertozzi, I, Vannucchi, AM, Gisslinger, H, Gisslinger, B, Finazzi, G, Ruggeri, M, Rodeghiero, F, Rambaldi, A, Gangat, N & Tefferi, A 2012, 'Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis', Blood, vol. 120, no. 3, pp. 569-571. https://doi.org/10.1182/blood-2012-01-407981
Barbui, Tiziano ; Thiele, Jürgen ; Carobbio, Alessandra ; Passamonti, Francesco ; Rumi, Elisa ; Randi, Maria Luigia ; Bertozzi, Irene ; Vannucchi, Alessandro M. ; Gisslinger, Heinz ; Gisslinger, Bettina ; Finazzi, Guido ; Ruggeri, Marco ; Rodeghiero, Francesco ; Rambaldi, Alessandro ; Gangat, Naseema ; Tefferi, Ayalew. / Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. In: Blood. 2012 ; Vol. 120, No. 3. pp. 569-571.
@article{997cf67d3a484ac0b8e75f392829f972,
title = "Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis",
abstract = "In the present study, we investigated disease characteristics and clinical outcome in young patients (<40 years) with World Health Organization (WHO)-defined essential thrombocythemia (ET) compared with early/prefibrotic primary myelofibrosis (PMF) with presenting thrombocythemia. We recruited 213 young patients (median age, 33.6 years), ncluding 178 patients (84{\%}) with WHO-defined ET and 35 patients (16{\%}) showing early PMF. Median follow-up time was 7.5 years. A trend for more overall thrombotic complications, particularly arterial, was seen in early PMF compared with ET. Progression to overt myelofibrosis was 3{\%} in ET and 9{\%} in early PMF, but no transformation into acute leukemia was observed. Combining all adverse events (thrombosis, bleeding, and myelofibrosis), the rate was significantly different (1.29{\%} vs 3.43{\%} of patients/year, P = .01) in WHO-ET and early PMF, respectively. In multivariate analysis, early PMF and the JAK2V617F mutation emerged as independent factors predicting cumulative adverse events.",
author = "Tiziano Barbui and J{\"u}rgen Thiele and Alessandra Carobbio and Francesco Passamonti and Elisa Rumi and Randi, {Maria Luigia} and Irene Bertozzi and Vannucchi, {Alessandro M.} and Heinz Gisslinger and Bettina Gisslinger and Guido Finazzi and Marco Ruggeri and Francesco Rodeghiero and Alessandro Rambaldi and Naseema Gangat and Ayalew Tefferi",
year = "2012",
month = "7",
day = "19",
doi = "10.1182/blood-2012-01-407981",
language = "English",
volume = "120",
pages = "569--571",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis

AU - Barbui, Tiziano

AU - Thiele, Jürgen

AU - Carobbio, Alessandra

AU - Passamonti, Francesco

AU - Rumi, Elisa

AU - Randi, Maria Luigia

AU - Bertozzi, Irene

AU - Vannucchi, Alessandro M.

AU - Gisslinger, Heinz

AU - Gisslinger, Bettina

AU - Finazzi, Guido

AU - Ruggeri, Marco

AU - Rodeghiero, Francesco

AU - Rambaldi, Alessandro

AU - Gangat, Naseema

AU - Tefferi, Ayalew

PY - 2012/7/19

Y1 - 2012/7/19

N2 - In the present study, we investigated disease characteristics and clinical outcome in young patients (<40 years) with World Health Organization (WHO)-defined essential thrombocythemia (ET) compared with early/prefibrotic primary myelofibrosis (PMF) with presenting thrombocythemia. We recruited 213 young patients (median age, 33.6 years), ncluding 178 patients (84%) with WHO-defined ET and 35 patients (16%) showing early PMF. Median follow-up time was 7.5 years. A trend for more overall thrombotic complications, particularly arterial, was seen in early PMF compared with ET. Progression to overt myelofibrosis was 3% in ET and 9% in early PMF, but no transformation into acute leukemia was observed. Combining all adverse events (thrombosis, bleeding, and myelofibrosis), the rate was significantly different (1.29% vs 3.43% of patients/year, P = .01) in WHO-ET and early PMF, respectively. In multivariate analysis, early PMF and the JAK2V617F mutation emerged as independent factors predicting cumulative adverse events.

AB - In the present study, we investigated disease characteristics and clinical outcome in young patients (<40 years) with World Health Organization (WHO)-defined essential thrombocythemia (ET) compared with early/prefibrotic primary myelofibrosis (PMF) with presenting thrombocythemia. We recruited 213 young patients (median age, 33.6 years), ncluding 178 patients (84%) with WHO-defined ET and 35 patients (16%) showing early PMF. Median follow-up time was 7.5 years. A trend for more overall thrombotic complications, particularly arterial, was seen in early PMF compared with ET. Progression to overt myelofibrosis was 3% in ET and 9% in early PMF, but no transformation into acute leukemia was observed. Combining all adverse events (thrombosis, bleeding, and myelofibrosis), the rate was significantly different (1.29% vs 3.43% of patients/year, P = .01) in WHO-ET and early PMF, respectively. In multivariate analysis, early PMF and the JAK2V617F mutation emerged as independent factors predicting cumulative adverse events.

UR - http://www.scopus.com/inward/record.url?scp=84864136100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864136100&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-01-407981

DO - 10.1182/blood-2012-01-407981

M3 - Article

C2 - 22700720

AN - SCOPUS:84864136100

VL - 120

SP - 569

EP - 571

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -